Chinese researchers have shown that adding the immunotherapy drug camrelizumab to the standard chemotherapy regimen CAPOX (capecitabine + oxaliplatin) dramatically improves outcomes for patients with advanced stomach or gastro‑esophageal junction cancer. In a large first‑line trial, the combination more than doubled overall survival compared with chemotherapy alone and also slowed disease progression. The study highlights how harnessing the body’s immune system can turn a traditionally grim prognosis into a more hopeful outlook. The article also touches on several related breakthroughs: scientists uncovered how the bacterium Helicobacter pylori rewires host metabolism, opening doors for new diagnostics; a gut microbe, Streptococcus anginosus, was found to fuel tumor growth via methionine production, suggesting a novel therapeutic target; and researchers demonstrated that differences in FGFR2b expression between primary tumors and peritoneal metastases can guide personalized targeted therapy. Other highlights include an AI‑driven tool that reads routine pathology slides to predict patient prognosis, updated Chinese gastric‑cancer treatment guidelines emphasizing precision medicine, and evidence that a diet rich in antioxidants—especially vitamin C and selenium—lowers cancer risk. Together, these findings point to a rapidly evolving landscape where immunotherapy, genetics, microbiology, and lifestyle all play a role in fighting stomach cancer.
Read moreIn an exclusive interview, Professor Chen Fadong of Shanghai Tongji Hospital explains how China is moving beyond copying foreign heart‑device designs and has created a breakthrough left‑atrial‑appendage (LAA) closure technology that uses magnetic fluid instead of a solid plug. This “liquid occlusion” can flow into the irregular shape of the LAA, sealing it completely and reducing three long‑standing problems: residual leaks, clot formation on the device, and slow healing of the heart tissue. Because the fluid hardens in place, the procedure is simpler and does not demand ultra‑precise hand‑skills from the surgeon, making it more accessible to hospitals across the country. Professor Chen says the innovation reflects China’s growing strength in medical‑material research and strong policy support, but acknowledges hurdles remain. Domestic material science still lags behind a century of Western experience, and the magnetic‑fluid approach needs larger, longer‑term clinical trials to prove safety and durability. He stresses that future device development must balance three goals—precise fit to each patient’s anatomy, minimally invasive safety, and affordable pricing—to bring stroke‑prevention solutions to more atrial‑fibrillation patients. The technology was highlighted at the 2026 Southern Cardiovascular Academic Conference in Guangzhou, signaling China’s shift from imitation to original leadership in heart‑device innovation.
Read more